Individualized Hormone Replacement Therapy Versus Ovarian Transplantation
Numerous studies conclude that risks and benefits of
hormonal replacement therapy (HRT) are dose-dependent [1]. The
pharmaceutical industry attempted to partially resolve the issue
of individualization of HRT by manufacturing at least six different
types of Minivelle patches (0.024mg, 0.0375mg, 0.05mg, 0.075mg,
and 0.1mg). The choices offered by the pharmaceuticals are useful
but fail to caliber dose based on the needs of the individual patient.
Each woman and her physician must decide whether ERT is an appropriate option for her. When making this decision, it is important to consider three factors that affect the risk-benefits of ERT: age at initiation, hormone dose, and route of administration [1]. Estrogen deficiency over a period of many years may result in significant, changes such as bone loss, vaginal and bladder atrophy, and/or other symptoms [1,2]. Therefore, the earlier after menopause ERT is initiated, the better the long-term outcome [1].
Each woman and her physician must decide whether ERT is an appropriate option for her. When making this decision, it is important to consider three factors that affect the risk-benefits of ERT: age at initiation, hormone dose, and route of administration [1]. Estrogen deficiency over a period of many years may result in significant, changes such as bone loss, vaginal and bladder atrophy, and/or other symptoms [1,2]. Therefore, the earlier after menopause ERT is initiated, the better the long-term outcome [1].
For More Open Access
Journals in Iris Publishers Please
click on:
https://irispublishers.com/
For More Articles in World Journal of Gynecology & Womens Health
https://irispublishers.com/wjgwh/
https://irispublishers.com/
For More Articles in World Journal of Gynecology & Womens Health
https://irispublishers.com/wjgwh/
